The granulocyte macrophage colony stimulating factor (GM-CSF) promoter contains a 10 bp element known as CK-1 or CD28RE that specifically responds to the co-stimulatory signal delivered to T cells via the CD28 surface receptor. This element is a variant NFκB site that does not function alone but requires an adjacent promoter region that includes a classical NFκB element, an Sp-1 site and a putative activator protein-1 (AP-1)-like binding site. The entire region is referred to as the CD28 response region (CD28RR). The GM-CSF CK-1 element has been shown to bind NFκB proteins, in particular c-Rel, whose binding and function is dependent on the architectural transcription factor HMGI(Y). It has been previously suggested that the nuclear factor of activated T cells (NFAT) family of proteins also plays a role in the activity of this region. We show here that recombinant NFATp but not AP-1 can bind to the GM-CSF CD28RR. NFATp present in activated Jurkat T cell extracts can also interact with the CD28RR. The binding of NFATp and Rel proteins requires the same core CK-1 sequences, and appears to be mutually exclusive. We investigated the functional significance of NFATp binding to CK-1 by overexpressing the protein in Jurkat T cells and found that NFATp cannot activate the CD28RR alone but can cooperate with signals generated by phorbol 12-myristate 13-acetate/calcium ionophore. The CD28RR is therefore a complex region that can bind and respond to a combination of transcription factors and signals.
Introduction
The efficient activation of naive T cells requires not only the or apoptosis (3) , and the co-activation of the CD28 receptor appears to overcome the anergic or apoptotic response and activation of the T cell receptor (TCR) by MHC-antigen complexes on antigen presenting cells (APC) but also the activates a proliferative response in the T cells (1) (2) (3) . TCR and CD28 generated signals are highly cooperative, presence of co-stimulatory signals provided by the APC. The most important of these co-stimulatory signals is provided by and result in high-level production of cytokines such as IL-2, IL-4 and granulocyte macrophage colony stimulating factor the interaction of the B7 molecules on the APC with CD28 on the T cell surface (1, 2) . TCR stimulation alone leads to anergy (GM-CSF) (4) . While IL-2 and IL-4 are involved in T cell proliferation and function, cytokines such as GM-CSF affect Table 1 . Sequences of oligonucleotides used in EMSA other arms of the immune system and help to coordinate the immune response. GM-CSF affects the differentiation, function -111 -67 and survival of cells of the myeloid lineage (5) . These cells GM CD28RR TGATAAGGGCCAGGAGATTCCACAGTTCAGGTAGTTCCCCCGCCTC a perform important functions in the inflammatory response to GMCK-1 TGATAAGGGCCAGGAGATTCCACAGTTCAGGTAGTT b,c foreign antigen as well as being involved in antigen presenta-
GMCK-1M -----------------gg-t---------------d tion (5). The coordinate expression, by activated T cells, of GMm19 ----------gtct----------------------

GMm21
---------------------------gtct-----cytokines that control distinct arms of the immune system is GMm23 ----------gtct-------------gtct-----clearly important in a correctly controlled immune response.
GMm25 -----------------cgg-----cgg--------
Much of the cooperative activation of cytokine expression calcium ionophore (I) leads to the induction of certain members of these families of transcription factors but this in turn drives only low-level promoter function (4, 6, 7, 11) . CD28 costimulation leads to an augmentation of the activity or level of The CD28RE (CK-1 elements) do not function as isolated some of these transcription factors and hence increased elements but require adjacent transcription factor binding transcription (4, 6, 7, 11) . NFκB family members, especially csites in the CD28RR for activity (6, 22) . The GM-CSF CD28RR Rel, are activated by CD28 (6, 12, 13) as are members of the also contains a consensus NFκB site that binds RelA/p50 AP-1 family via the activation of JNK (14, 15) . Whether CD28 heterodimers and, although not itself responsive to CD28 co-stimulation leads to a qualitative or simply a quantitative activation, appears to play a important role in the activity of change in these transcription factors has yet to be determined. this region (6) . Recently it has been shown that an AP-1-like Specific regions that are required for response to CD28 site in the CD28RR of IL-2 is required for activity together have been identified in the promoters of the IL-2 and GMwith the CD28RE (22), although there is some controversy CSF genes, and are referred to as the CD28 response regions concerning the proteins that operate on this AP-1 site (22-(CD28RR) (4, 6, 7, 11) . These CD28RR contain an element 25). The GM-CSF CD28RR contains a very weak match to a known as either CK-1 in the GM-CSF promoter (6, 16) or consensus AP-1 site but mutation of this site does not affect CD28RE in the IL-2 promoter (4,7) that is essential for a CD28 the ability of the HTLV-1 transactivator, Tax, to activate this response. The proteins that bind to and activate the CD28RR region (26) . have been difficult to define. It has been shown that the CK-1
The DNA binding domains of NFκB and NFAT proteins share or CD28RE is a variant NFκB site that binds RelA homodimers a low degree of sequence similarity and three-dimensional as well as c-Rel-containing complexes (6, 17) . NFκB proteins structure (27, 28) . The similarity is also manifested in some are activated in a biphasic fashion in T cells (13, 18, 19) . Within sequence similarity in their binding sites on DNA (28). It is 10 min of activation there is an accumulation of RelA and p50 not surprising, therefore, that there has been a report that in the nucleus that peaks at around 30 min but returns to NFAT-like proteins can bind to the GM-CSF CK-1 element (29) near basal levels by 1 h. The second wave of NFκB activation but their function is unknown. Here, we have characterized is characterized by a shift in the NFκB family members that the binding of NFATp to the GM-CSF CD28RR and investigated are found in the nucleus, with c-Rel and RelB dominating the the functional consequences of this binding. later activation that peaks at~6 h (18, 19) . CD28 activation appears to have its major impact on the late activation of cMethods Rel and thus not only increases the level of activation but also prolongs the signal (6, 13, 19) . The CD28RR does not Plasmids and oligonucleotides respond to signals that only activate the early induction of RelA and p50 such as PMA or tumor necrosis factor (TNF)
The pGMCK-1(2) reporter plasmid contains two copies of the GM-CSF CD28RR (Table 1) cloned upstream of the thymidine (6, 17) . The late induction of c-Rel leads to a large increase in protein binding to the CD28RR (6, 20) which is thought to kinase basal promoter and the luciferase reporter gene, and has been previously described (26) . The expression vector be essential for the activity of this element (6) . There is evidence both from in vitro studies and from c-Rel deficient pRc/CMV was obtained from Invitrogen (San Diego, CA) and pCMVp65(ϩ) contains the Rel homology domain of RelA mice that c-Rel plays a vital role in CD28 activation of cytokine genes (6, 21) .
cloned downstream of the CMV promoter and has been described previously (17). The NFATp expression plasmid, in 0.5ϫTBE, dried and autoradiographed. Conditions for EMSA using recombinant HMGI(Y) were as above but with pLGPNFAT1c, contains the 'c' isoform of NFATp (NFAT1) cloned into the plasmid pLGP3 (30) and was a gift from Dr the addition of 2 mM MgCl 2 to the binding reactions. Anjana Rao.
Cell culture and transfection All oligonucleotides were synthesized at Bresatec (Adelaide, Australia) except Sp-1 which was purchased from Jurkat T cells were maintained in RPMI containing 10% FCS, Promega (Madison, WI). The sequences of the oligonucleosupplemented with L-glutamine, penicillin and gentamicin tides used for gel-shift analysis are shown in Table 1 .
antibiotics (6) . Cells were electroporated at 250 V with a Double-stranded oligonucleotide probes for gel shift were capacitance of 960 µF using a BioRad Gene Pulser. Approxiprepared by end-labeling with [γ-P 32 ]ATP using T4 polynucleomately 4.5ϫ10 6 cells were electroporated in 300 µl of RPMI tide kinase as previously described (6) .
containing 20% FCS per transfection. Routinely, 10 µg of pGMCK-1(2) reporter plasmid was used in transfections.
Antibodies
For the overexpression study, 10 and 20 µg of expression The antibody against NFATp (R59) was a gift from Dr A. Rao constructs pCMVp65(ϩ), pLGPNFAT1c and pRc/CMV were and is specific for NFATp (31) . Polyclonal p50 and c-Rel co-transfected with reporter plasmid. Cells were allowed to antibodies were purchased from Santa Cruz Biotechnology recover from transfection for 24 h, and then stimulated for 8 h (Santa Cruz, CA). Polyclonal RelA antibody (32) was provided with 20 ng/ml PMA, 1.0 µM calcium ionophore (A23187) and by Dr Steve Gerondakis. Where indicated, 0.5 µl of anti-NFAT a 1:10,000 dilution of anti-CD28 ascites (WA93165; Bristol (R59), anti-c-Rel and anti-RelA was used in DNA binding Myers Squibb, Seattle, WA). assays.
Reporter assays Recombinant proteins
Transfected cells were lysed by three cycles of freeze-thaw. Recombinant RelA protein was a generous gift from Dr Steve
The protein concentration of cell lysates was determined by Gerondakis and was prepared as previously described (17).
the Bradford assay as previously described (6) . Luciferase Purified recombinant NFATp protein and truncated c-fos and reporter assays were carried out as described (26) . Cell c-jun proteins were prepared and purified as described extract (10 µg) was assayed in triplicate for each transfection. (33) . The expression vector p∆M1.1 which contains the Rel homology domain of human c-Rel truncated at amino acid Results 288 was a gift from Dr Charles Kunsch and was used to produce recombinant c-Rel protein as described (34) . The c-
The proteins that bind to the CK-1 element depend on the Rel protein was used as a crude Escherichia coli lysate in stimulation conditions gel-shift assays. Recombinant p50 protein was purchased from Promega. Purified recombinant high-mobility group proThere has been a previous report showing that a NFAT-like activity bound to the GM-CSF CK-1 element (29). To further tein I(Y) [HMGI(Y)] was a gift from Dr Raymond Reeves and has been previously described (6) . The amount of characterize this activity, we initially activated Jurkat T cells with I alone to avoid activation of NFκB proteins that could recombinant proteins used in gel-shift analysis was determined empirically by titration experiments. Purified recombinbind to the CK-1 element. Jurkat T cells treated with I alone contained an inducible complex that bound to the GM-CSF ant c-fos and c-jun were provided by Dr David Tremethick, and were used as previously described (35) . CD28RR (Fig. 1a) . This complex co-migrated with a previously characterized NFATp complex that bound to a NFAT binding Electrophoretic mobility shift assay (EMSA) site in the GM-CSF enhancer (GM430) (Fig. 1a) . The GM430 element is the NFAT portion of a NFAT/AP-1 composite site Nuclear extracts from Jurkat T cells were prepared as described by Schreiber et al. (36) . An aliquot of 10 µg of that can act as a strong NFAT binding site in the absence of AP-1 (33, 38) . The complex was present at a range of times nuclear extracts was incubated in the presence of 0.2 ng of radiolabeled oligonucleotide probe with 25 mM HEPES, pH examined from 30 min to 6 h (data not shown). The behavior of this complex was identical to that of the NFATp complex 7.9, 100 mM NaCl, 2.5 µg poly(dI:dC), 1 mM Tris, 0.5 mM EDTA, 0.5 mM EGTA, 0.5 mM DTT and 0.5 mM PMSF in a binding to the GM430 element in that it was supershifted by an anti-NFATp antibody (Fig. 1a , lanes 4 and 8) but not by final volume of 15 µl (37). Binding was carried out for 15 min at room temperature. The binding reactions were separated pre-immune serum or an antibody to RelA (Fig. 1a , lanes 2/3 and 6/7). The majority of the NFAT complex binding to the on a 5% non-denaturing acrylamide gel in 0.5ϫTBE (0.5 mM Tris, 42 mM boric acid and 1 mM EDTA, pH 8.3) at 200 V GMCK-1 probe was supershifted with the NFATp antibody as described above. An antibody to NFATc did not supershift for~2 h, dried and autoradiographed. For assays using recombinant proteins, 5 µl of protein diluted in 0.1 mM EDTA, the complex (data not shown). Therefore, all subsequent experiments concentrated on the analysis of NFATp. We have 100 mM KCl, 20 mM HEPES pH 7.8, 5 µg/ml BSA and 20% glycerol was incubated for 15 min at room temperature with previously shown that NFκB/Rel proteins can bind to the GM-CSF CD28RR in extracts prepared from cells stimulated 0.2 ng probe, 200 ng dI:dC in a binding buffer containing 30 mM KCl, 16.6 mM NaCl, 20 mM HEPES (pH 7.9), 10%
with PMA/I, with or without CD28 activation (6) . In order to determine whether NFATp also binds to the CD28RR under glycerol, 1 mg/ml leupeptin, 1 mg/ml aprotinin, 1.5 mM DTT and 0.15 mM PMSF in a final volume of 15 µl. This reaction these stimulation conditions, antibody supershift experiments were performed on extracts made at 30 min or 6 h following was then separated on a 5% non-denaturing acrlyamide gel PMA/I/CD28 activation with binding conditions optimized for whose binding capacity is unknown. The presence of c-jun NFAT (37) . As expected supershifts were observed with and c-fos was examined in complexes formed on the GMantibodies to RelA or c-Rel with c-Rel being dominant at 6 h CSF CD28RR from nuclear extracts prepared from cells (Fig. 1b , lanes 4/5 and 10/11). The p50 antibody did not stimulated with PMA/I/CD28 for 6 h. Antibodies to c-Rel and generate a specific supershift as previously described but NFATp generated supershifts when added to these binding did result in non-specific smearing when a large amount of reactions as described above, but the c-fos or c-jun antibodies NFκB binding was observed (Fig. 1b, lane 9) . The NFATp did not (Fig. 1c, lanes 10-13) . On the other hand, the c-jun antibody generated a weak supershifted complex at 30 min and NFATp antibodies supershifted complexes binding to the and a stronger supershifted complex at 6 h implying that NFAT/AP-1 IL-2 probe, which forms a cooperative NFAT/AP-1 NFATp could bind to the CD28RR under these conditions complex, but c-Rel antibody did not (Fig. 1c, lanes 3-5) . The (Fig. 1b, lanes 6 and 12) . The disappearance of the NFATp c-fos antibody has been shown to inhibit recombinant c-fos/ band is more obvious in Fig. 1(a) because there was no NFκB c-jun binding to the IL-2 CD28RR (data not shown). protein in the I-treated cells. When NFκB proteins are present These results show that NFATp but not AP-1 can bind to they migrate at the same position as the NFAT complexes the GM-CSF CD28RR in extracts from cells stimulated either making it difficult to distinguish a reduction in NFATp binding with I alone or under conditions such as PMA/I/CD28 where (Fig. 1b) .
NFκB and also AP-1 are activated. In many of the cytokine promoter and enhancer regions NFATp functions as a complex with AP-1 bound to an adjacent Recombinant NFATp but not AP-1 binds to the GM-CSF site (40) , and cooperative binding of NFATp and AP-1 is CD28RR observed when the NFAT and AP-1 binding sites are correctly
To further analyze the binding of NFATp and c-fos/c-jun (AP-1) spaced (33) . Immediately downstream from the CK-1 element is a very weak match (CAGTTCA) to a consensus AP-1 site to the CD28RR we used recombinant proteins to perform EMSA experiments with the GMCK-1 and IL-2CD28RR oligoWe also used truncated c-fos/c-jun proteins that we have previously shown can form cooperative complexes on comnucleotides.
Both the GMCK-1 and IL-2CD28RR oligonucleotides could posite NFAT/AP-1 sites (33) to confirm the lack of cooperation between NFAT and AP-1 on either the IL-2 or GM-CSF bind recombinant NFATp, but only the IL-2 and not the GM-CSF CD28RR bound AP-1 (Fig. 2a, lanes 1 and 7) . There CD28RR. As expected NFATp and the truncated c-fos and cjun proteins bound cooperatively to a previously described was no evidence of higher-order complex formation when NFAT and AP-1 were present on either probe (Fig. 2a, lanes composite NFAT/AP-1 site from the IL-2 promoter (33) (Fig.  2b, lanes 1-3) . Each of the proteins bound independently to 3 and 9), but an apparent increase in NFATp binding strength was observed on both probes in the presence of AP-1 (Fig. the IL-2 CD28RR (Fig. 2b, lanes 4-6) , but only NFAT bound to the GMCK-1 (Fig. 2b, lanes 7-9) . The binding of NFATp to 2a, lanes 3 and 9) (see below). The addition of an anti-c-jun antibody to the binding reactions reduced the AP-1 complex the GMCK-1 probe and AP-1 to the IL-2 CD28RR was very weak here due to the low concentrations used in these assays on the IL-2 probe but had no effect on the NFATp complexes binding to either probe (Fig. 2a, lanes 4 and 10) , whereas in order to detect cooperative binding. An apparent increase in NFATp binding to the GMCK-1 probe in the presence of the addition of a NFATp antibody inhibited NFATp binding to both probes (Fig. 2a, lanes 5 and 11) . The presence of the AP-1 and AP-1 binding to the IL-2 probe in the presence of NFATp was observed at the low concentrations of protein NFAT antibody or pre-immune serum leads to an apparent increase in AP-1 binding to the IL-2 CD28RR and a faint APused here. The reason for such increases, that vary depending on the binding conditions, is not clear. These results verify 1 band appearing with the GMCK-1 probe which could be a non-specific effect due to an increase in the protein concentrathe results observed with nuclear extracts showing that the GM-CSF CD28RR binds NFATp but not AP-1 proteins. tions in the binding reactions.
We next defined the sequence requirements for NFATp binding to the GM-CSF CD28RR. NFATp could not bind to a CK-1 mutant that we have previously characterized as a nonfunctional mutant that cannot bind RelA (Fig. 2c) . The more slowly migrating band in the NFATp lane most likely represents a NFATp dimer which forms at high concentrations of protein (see below). Using a series of mutations across the GMCK-1 probe (Table 1) as competitors in gel-shift assays we found that mutations in the 5Ј end of the CK-1 element (Fig. 2d,  m19 and m23) or outside the CK-1 element (Fig. 2d, m21) did not greatly affect NFATp binding but that mutations that included the 3Ј end of CK-1 were weak competitors of NFATp binding (Fig. 2d, m25) . These results show that NFATp binds to the core CK-1 element as has previously been determined for NFκB proteins (6, 20, 26) .
Mutually exclusive binding of NFATp and NFκB proteins to the GM-CSF CK-1 element
Because NFATp and NFκB proteins both bound to the CK-1 element in the CD28RR, we tested whether they could bind simultaneously or form heteromeric complexes on the DNA. When NFATp and RelA were both added to GMCK-1 binding reactions, we observed that each protein appeared to bind independently and there was no evidence for the formation of heteromeric or higher-order complexes (Fig. 3a) . In fact there appears to be an inhibition of NFATp binding by the addition of RelA even in the presence of excess probe (Fig.  3a , cf. lanes 2 and 9/10). When increasing amounts of RelA (Fig. 3b, lanes 2-6) , c-Rel (Fig. 3c, lanes 2-7) or p50 (Fig.  3b, lanes 8-12) were titrated with a fixed amount of NFATp in DNA binding assays again no higher-order or heteromeric complexes appeared. Both RelA and to a lesser extent c-Rel but not p50 appeared to inhibit NFATp binding in a dosedependent manner (Fig. 3b and c) . This was not due to competition for limiting probe as the probe concentration was always in excess in the binding reactions. p50 binding to the GMCK-1 probe was observed here because of the large RelA and c-Rel but not p50 bound to the GMCK-1 probe but and EMSA were performed as described in Fig. 3 . The EMSA gels none of these proteins bound to the GM430 probe (Fig. 4a shown here were repeated with identical results at least 3 times. and b). The truncated NFκB proteins generated complexes that migrate lower on the gel than full-length NFAT proteins from cells. As was observed for recombinant NFATp, no on the architectural protein HMGI(Y), and that HMGI(Y) was additional complexes were detected in these experiments. required for CD28RR function (6), we determined whether Some inhibition of binding of NFATp was observed to both HMGI(Y) affected NFATp binding to the CD28RR. When the GMCK-1 and GM430 probes with the addition of RelA but increasing amounts of HMGI(Y) was mixed with NFATp prior not c-Rel or p50 (Fig. 4a and b, lanes 5-7, 8-10 and 11-13) .
to DNA binding, a dose-dependent increase in NFATp binding Taken together these results imply that NFATp and NFκB bind was observed to both the GMCK-1 and IL-2CD28RR oligonuto the GMCK-1 element independently and that binding is cleotides ( Fig. 5a and b ). An inhibition of binding was mutually exclusive.
observed at the highest concentrations used. We also
HMGI(Y) enhances NFATp binding to the CK-1 elements
observed a similar increase in NFATp binding to the GM430 site, a site that does not bind HMGI(Y) alone (Fig. 5c ). The Since we had previously shown that the binding of c-Rel but not RelA to the GM-CSF and IL-2 CD28RR was dependent decrease in NFATp binding at high concentrations of HMGI(Y) of the sequence of these elements showed that there is a GGA/TCC palindromic sequence across the GM-CSF CK-1 element but not the IL-2 CD28RE or the GM430. The core of a NFAT site is a GGAA/G element and therefore it is possible that two molecules of NFAT could bind to each arm of the palindrome. We examined the sequences of other CK-1-like elements, and found that the ICAM-1 and the IL-3 CK-1-like elements also contained GGA/TCC palindromes. The ICAM-1 site but not the IL-3 CK-1 element can bind HMGI(Y) (data not shown). In the case of ICAM-1 a possible dimeric NFATp band was detected together with the increased NFATp binding seen with the addition of HMGI(Y) (Fig. 5d ). In the case of IL-3, NFATp can bind efficiently to the site alone and a strong dimeric complex is also observed (data not shown). The formation of these complexes is inhibited by the addition of antibodies to NFATp or HMGI(Y) (data not shown). 
NFATp can potentiate the function of the GM-CSF CD28RR
RelA (lanes 5-7), c-Rel (lanes 8-10), p50 (lanes 11-13) or crude
To investigate whether NFATp contributes to the activity of the activated the CD28RR reporter but NFATp expression did not (Fig. 6a) . A combination of NFATp and RelA had no increased effect over RelA alone showing that the proteins could not synergize with each other (Fig. 6a) . Titration experiments using different amounts of each plasmid gave the same result (data not shown). It has been shown that NFATp translocation to the nucleus requires its dephosphorylation by calcineurin phosphatase, which is activated by increased levels of intracellular Ca 2ϩ (41, 42) . It is possible that none of the NFATp expressed in the experiments above can translocate to the nucleus. We therefore examined whether co-expressing a constitutively active calcineurin phosphatase would lead to NFATp activation. No increased activity for NFATp alone or synergy with RelA were observed (data not shown). In the same experiments the pGMCK-1(2) construct responded to PMA/I activation and showed an increased activity in response to CD28 co-stimulation (Fig. 6a) as previously described (6). We next examined whether activation of the NFATp-transfected cells could unmask a role for NFATp in CD28RR I alone but was activated by PMA/I (Fig. 6b) . Transfection of bands are indicated. The EMSA shown here was repeated 3 times.
the NFATp expression plasmid did not overcome the lack of response to P or I alone but with a combined PMA/I signal a highly cooperative effect was observed (Fig. 6b) . These results show that activating the nuclear translocation of NFAT that was observed with the GMCK-1 and IL-2 sites was not, however, observed here (Fig. 5c) .
with I treatment alone does not lead to NFAT function on this region, as we had observed with active calcineurin expression, The addition of HMGI(Y) also appeared to promote the formation of a more slowly migrating complex, that could but that signals activated by P treatment are also required for cooperative activity on the CD28RR. represent a NFATp dimer, on the GMCK-1 probe but not the IL-2CD28RR nor the GM430 probes (Fig. 5a ). An examination
The activity of the CD28RR can be increased by stimulation of the CD28 signaling pathway (6). We therefore investigated whether NFATp overexpression could also cooperate with all three signals or was substituting for the CD28 signal in the cooperation with PMA/I observed here. The results showed that NFATp expression cooperated with PMA/I in the presence of CD28 signals to lead to increased levels of activity from the CD28RR (Fig. 6c) . While NFATp expression enhanced both PMA/I and PMA/I/CD28 activity, the ratio of the PMA/I/ CD28 to PMA/I response was not affected by the presence of NFATp. We also examined whether NFATp expression could cooperate with the combinations of PMA ϩ CD28 or I ϩ CD28 to activate the CD28RR. These combinations of signals alone could not activate the CD28RR and expressing NFATp did not compensate for this lack of activity (Fig. 6c) . These results imply that a combination of signals activated by PMA/I and CD28 are required for the function of the CD28RR, and that NFATp cannot substitute for but can cooperate with these signals.
Discussion
The CD28RR of the GM-CSF gene is a complex binding site for many different transcription factors and requires the activation of multiple signaling pathways for function. This is illustrated here by the finding that the GM-CSF CD28RR does not respond to PMA or I signals alone but requires both signals for activity. CD28 activation together with the above signals optimally activates the CD28RR, but CD28 activation cannot combine with PMA or I individually to activate the CD28RR. The need for multiple signals is borne out at the level of transcription factor binding to the CD28RR. We have previously shown that NFκB family proteins play an important role in the function of the GM-CSF CD28RR (6) . Experiments described here show that NFATp may also play a role in GM-CSF CD28RR activity. There was an earlier report that NFATlike proteins bound to the GM-CSF CK-1 element but the exact identity and functional consequences were not investigated (29). We confirmed this interaction using recombinant NFATp and showed that NFATp binding required the TTCC/ Fig. 6 . Activation of the GM-CSF CD28RR by NFATp in Jurkat T cells. (a) Jurkat T cells were transfected by electroporation with the pGMCK-1(2) reporter construct (10 µg) and expression constructs for RelA and NFATp either alone or together at the indicated amounts. Cells without the expression constructs or those with lower amounts were co-transfected with a blank CMV expression plasmid to ensure equal DNA levels in each transfection. Transfected cells were either left unstimulated or stimulated with PMA (20 ng/ml) and I (1.0 µM) (PMA/ I) in the presence or absence of a CD28 activating antibody (1:10,000 dilution of ascites WA93165 from Bristol Myers Squibb) (PMA/I/CD28) 24 h later. Cells were harvested 8 h after stimulation and cell extracts prepared for luciferase assays. The data is presented as mean luciferase activity from three independent transfection with duplicates within each experiment. (b) Jurkat T cells were transfected with a NFATp reporter plasmid (10 µg) or a blank CMV plasmid (10 µg) and the pGMCK-1(2) reporter plasmid and stimulated 24 h later with PMA (P), I alone or together (PMA/I) for 8 h before harvesting for luciferase activity. The data is presented as in (a). (c) Jurkat T cells were transfected as described in (b) and were stimulated with combinations of PMA (P), I and the activating CD28 antibody (C) at the same concentrations as described for (a).
GGAA bases of the CK-1 element. This sequence has been IL-2 CD28RR, functionally cooperate with Rel proteins binding to the CD28RE. This cooperation is not at the level of DNA shown to be the core consensus required for NFAT binding to DNA (42) and is part of the already defined binding site binding since the combination of AP-1 and c-Rel appear to bind independently to the IL-2 CD28RR (J. Attema and M. F. for Rel proteins across CK-1 (6, 26) . The Rel and NFAT families of proteins share some similarity across their DNA binding Shannon, unpublished) . AP-1 and NFATp also bind independently to the IL-2 CD28RR and not in a cooperative fashion domains, and display similar DNA contacts across the GGAA region of their binding sites (42). However, NFAT generally as has been shown for many other NFAT/AP-1 sites. The cooperative binding of these proteins depends on the approbinds as a monomer whereas Rel proteins bind as obligate dimers (reviewed in 42,43). Interestingly, it appears that two priate spacing of the binding sites (33) , and the NFAT and AP-1 sites of the IL-2 CD28RR are not appropriately spaced molecules of NFATp may bind to some of the CK-1 sites examined here and this appears to correspond to the presto fit this model. Mutation of the IL-2 AP-1 site abolishes the response of the region to HTLV-1 Tax and CD28 activation ence of a GGA/TCC palindromic sequence across the region. The ability to form such a dimer of NFATp may alter the (24,25). On the other hand, in agreement with the lack of AP-1 binding, we have previously shown that mutating the putative functional significance of NFAT binding to the CK-1 elements. Similar dimeric binding of NFATp has previously been reported AP-1 region of the GM-CSF CD28RR has no effect on its response to HTLV-1 Tax nor to PMA and I treatment (20 and on the TNF-α promoter, but the functional significance is not clear (44). The architectural protein HMGI(Y) appears to data not shown). These data suggest that there is a distinction between the proteins that bind to and activate the IL-2 and promote NFATp binding to the CD28RR. We have previously shown that HMGI(Y) promotes c-Rel binding to the CD28RR, GM-CSF CD28RR, and implies that different physiological signals may act on each of the genes. and is essential for the function of the GM-CSF and IL-2 CD28RR (6). The fact that it also supports NFATp binding NFATp activity on the CD28RR is only manifested when the transfected cells are stimulated with both PMA and I. suggests that it plays a central role in the formation and architecture of many complexes on the CD28RR.
Stimulation of the cells with I alone or co-expression of a constitutively active calcineurin, both of which should lead to NFATp present in nuclear extracts from activated T cells can also bind to the GM-CSF CD28RR. This binding was NFATp translocation to the nucleus, were not sufficient for NFATp function on the CD28RR. NFATp has been shown observed both in extracts where NFκB/Rel proteins were absent (I treated cells) or where there were high levels of to activate other cytokine promoter elements under these conditions (45). While NFATp expression enhanced PMA/I or RelA and c-Rel (PMA/I and CD28 treated cells). Similar complexes of proteins including NFATp and NFκB/Rel proteins PMA/I/CD28 activation it did not appear to alter the ratio of the PMA/I/CD28 to PMA/I responses. This suggests that the have been observed binding to the IL-2 CD28RR (45). It is clear that the Rel and NFATp proteins do not form heteromeric CD28 signaling pathway does not cooperate with or influence NFATp function, whereas the PMA/I signals do. Under the complexes on the DNA and appear to bind independently. In fact an apparent cross-inhibition of binding by these proteins conditions where NFATp generates increased activity, NFκB/ Rel proteins are also activated and bind to the CD28RR. We was observed but the significance of this inhibition is unclear since NFATp binding can be observed in gel-shift experiments can find no evidence either at the functional level or DNA binding level that NFATp and NFκB proteins can cooperate under stimulation conditions in cells (PMA/I/CD28) that generate large amounts of NFκB proteins. Attempts to detect NFAT/ on the GM-CSF CD28RR and thus it is unlikely that the increased activity is a result of NFAT/NFκB cooperation at this RelA interactions in the absence of DNA, that could account for such cross-inhibition, have shown that there may be a level. There are several other possible explanations for the finding that NFATp cooperates with both I and PMA generated weak but unstable interaction (data not shown). It is possible that the NFAT and NFκB proteins, binding independently, play signals. Firstly, it is possible that while NFATp is translocated to the nucleus by the I signal it needs to cooperate functionally a separate time-or stimulus-dependent role in the activation of this region. Proteins such as NFATp and RelA are activated with PMA-activated transcription factors that have yet to be identified. Our experiments imply that these factors are not within minutes of cell stimulation (18,42,43), whereas c-Rel requires several hours of activation to reach high levels in the NFκB/Rel or AP-1-like proteins. A second possible explanation for the requirement for both PMA and I signals to cooperate nucleus (6, 13, 18, 19) . It has been shown that RelA and NFATp can interact with the histone acetylases p300/CBP (46, 47) , with NFATp relates to the fact that NFATp can be translocated to the nucleus by an increase in intracellular calcium but may and it is possible that they play an early role in recruitment of the acetylases to the promoter and reorganization of the require a second signal for activity. There is evidence that PMA-activated signals can affect NFAT function but the mechchromatin. On the other hand, c-Rel may play a role in prolonging the activation of the promoter via a different anism is not understood (42). The GM-CSF CD28RR appears to be capable of binding mechanism.
Our analysis of the GM-CSF CD28RR has shown that cand reacting to different combinations of transcription factors [NFAT, c-Rel, RelA and HMGI(Y)] all of which are important fos/c-jun does not bind to or form complexes with NFATp on this site. This is in contrast to the IL-2 CD28RR where, as in the regulation of T cell activation. Each factor may play an individual time-or stimulus-dependent role in the activity of shown here and by others, AP-1 family members can bind and are required for the activity of this region (22-25,48).
this region. Whether any of these activities are redundant or exclusive remains to be determined. The ability to bind these There has been recent evidence presented that AP-1 (24, 25) or activating transcription factor/cAMP response element different factors may confer on the CD28RR a unique role in sensing the relative levels of each of these important factors binding protein (23) , proteins binding to the AP-1 site of the
